Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z9LP
|
|||
| Former ID |
DNCL002755
|
|||
| Drug Name |
RP101
|
|||
| Synonyms |
SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Infectious disease [ICD-11: 1A00-CA43.1] | Phase 2/3 | [1] | |
| Pancreatic cancer [ICD-11: 2C10] | Phase 2/3 | [1] | ||
| Company |
RESprotect
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13BrN2O5
|
|||
| Canonical SMILES |
C1C(C(OC1N2C=C(C(=O)NC2=O)C=CBr)CO)O
|
|||
| InChI |
1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1
|
|||
| InChIKey |
ODZBBRURCPAEIQ-PIXDULNESA-N
|
|||
| CAS Number |
CAS 69304-47-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
626301, 7886385, 10299946, 12013052, 14753290, 14777594, 17404738, 36889073, 47662505, 50061728, 50105913, 50105914, 51091587, 53777281, 57404760, 74891762, 81063726, 92303475, 96099884, 103202903, 104636938, 124749513, 126664401, 135027036, 137117130, 137241573, 137267153, 144079989, 144204764, 151973399, 160845783, 162202464, 163564129, 171579601, 174530396, 179150950, 180682076, 184547605, 186024303, 189562911, 198936870, 223679053, 223702471, 224424196, 226474785, 226508398, 251971262, 252072343, 252134145, 252346818
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Resulting Metabolite | Bromovinyluracil | |||
| Metabolic Effect | Increase toxicity | |||
| Description | Brivudine can be metabolized to Bromovinyluracil by Bacteroides ovatus, which results in the increase of the drug's toxicity. | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Resulting Metabolite | Bromovinyluracil | |||
| Metabolic Effect | Increase toxicity (hepatotoxicity) | |||
| Description | Brivudine can be metabolized to Bromovinyluracil by Bacteroides thetaiotaomicron, which results in the increase of the drug's toxicity (hepatotoxicity). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [2] | |||
| Metabolic Reaction | N-dealkylation | |||
| Resulting Metabolite | Bromovinyluracil | |||
| Metabolic Effect | Increase toxicity (hepatotoxicity) | |||
| Description | Brivudine can be metabolized to Bromovinyluracil by gut microbiota through N-dealkylation, which results in the increase of the drug's toxicity (hepatotoxicity). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymidine kinase 1 (TK1) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020300) | |||
| REF 2 | Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019 Feb 8;363(6427):eaat9931. | |||
| REF 3 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.